ENDRA Life Sciences Awarded Two Additional Chinese Patents for its TAEUS® System
July 11 2022 - 8:00AM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the
Chinese National Intellectual Property Administration has issued
two new patents to ENDRA, Chinese Patent No. ZL 2020 8 00151255
(the ‘255 patent) titled “Systems and Methods for Thermoacoustic
Transducer Optimization” and Chinese Patent No. ZL 2020 8 00151433
(the ‘433 patent) titled “Method and System for Reconstructing a
Thermoacoustic Image.”
“We are delighted to announce our 14th and 15th issued patents
in China, which provide intellectual property protection through
2040. These patents demonstrate our commitment to protecting the
novel technology used in our TAEUS System in Asia’s largest
healthcare market with an estimated 350 million people affected by
NAFLD-NASH," stated ENDRA's Chairman and Chief Executive Officer
Francois Michelon. "Our global intellectual property portfolio has
increased to 50 issued patents as we expand protection of our core
technology in priority global markets.”
The ‘255 patent relates to characterizing a given system by
placing a small, high-contrast object called an impulse in a field
of view, and using the resulting impulse data to optimize
transducer functionality. Examples of transducer functionality are
transducer geometry, an arrangement of transducer elements and a
distribution of transducer elements. The ‘255 parent patent is U.S.
Patent No. 10993624. The ‘433 patent utilizes a view and
position-specific kernel to correct for differences in the relative
relationship between a transducer element array and an object
within a region of interest to be imaged. The ‘433 parent patent is
U.S. Patent No. 10687789.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 500,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and
inflammation (NASH), chronic liver conditions that affect over one
billion people globally, and for which there are no practical
diagnostic tools. Beyond the liver, ENDRA is exploring several
other clinical applications of TAEUS®, including visualization of
tissue temperature during energy-based surgical procedures. For
more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” "anticipate," “attempt,” "believe,"
"could," "estimate," "expect," “forecast,” “future,” "goal,"
“hope,” "intend," "may," "plan," “possible,” “potential,”
“project,” "seek," "should," "will," “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
our development efforts, including the timing for receipt of
required regulatory approvals and product launches; future
financial position and projected costs and revenue; expectations
concerning ENDRA's business strategy; ENDRA’s ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; and ENDRA’s ability to protect its intellectual property.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others: the ability to raise additional capital in
order to continue as a going concern; the ability to obtain
regulatory approvals necessary to sell ENDRA medical devices in
certain markets in a timely manner, or at all; the ability to
develop a commercially feasible technology and its dependence on
third parties to design and manufacture its products; the impact of
COVID-19 on ENDRA’s business plans; the ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission. You should
not rely upon forward-looking statements as predictions of future
events. The forward-looking statements made in this press release
speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220711005025/en/
Irina Pestrikova Senior Director, Finance investors@endrainc.com
www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations (310)
691-7100 YBriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024